Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

It has other candidates in its late-stage obesity pipeline, headed by CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide with semaglutide. Phase 3 results reported ...

The stock was trading down more than 5.5% at the time of writing following the revelation that in the REDEFINE 2 trial, CagriSema (cagrilintide and semaglutide) achieved a weight loss of 15.7% ...

Citing data from its REDEFINE 1 trial, Novo Nordisk (NVO) added that the once-weekly injectable, comprising amylin-analog cagrilintide and its GLP-1 receptor agonist semaglutide, was safe and well ...

CagriSema is a combination of cagrilintide — a nascent form of weight loss treatment known as an amylin analog — and semaglutide, the active ingredient in Wegovy. Headline results from a ...

Novo hoped to combine Cagrisema (cagrilintide), an amylin analogue, with semaglutide, a glucagon like peptide ("GLP-1") agonist, and trigger >25% weight loss in patients, to best Lilly's Zepbound ...